NCT05088356 2026-04-08
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Stanford University
Phase 1 Recruiting
Clinical Trials
68 trialsNCT06207799 2026-02-19
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06158828 2026-02-13
ABCD-NK
Washington University School of Medicine
Phase 1/2 Recruiting
NCT07188090 2025-11-28
HSCT
Thomas Jefferson University
Phase 2 Recruiting
NCT02570542 2025-11-26
Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03746080 2025-11-14
Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma
Stanford University
Phase 2 Completed
NCT01526096 2025-11-05
Stem Cell Transplantation for Patients With Multiple Myeloma
University of Chicago
Phase 1 Completed
NCT01318317 2025-04-25
Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1/2 Active not recruiting
NCT01186224 2025-03-17
PHANTASTIC
University of Liverpool
Phase NA Completed
NCT04177810 2024-02-23
Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03406091 2024-02-20
Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients
Fondazione EMN Italy Onlus
Completed
NCT06141304 2023-11-21
Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT
The First Hospital of Jilin University
Phase 2 Unknown
NCT03240861 2023-11-01
NYESO SCT
Jonsson Comprehensive Cancer Center
Phase 1 Terminated
NCT05510544 2023-03-13
Plerixafor for Poorly Mobilized Lymphoma
Peking University
Phase 4 Unknown
NCT01746173 2023-01-30
CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT03612466 2022-10-14
A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy
Albert Einstein College of Medicine
Phase 1 Withdrawn
NCT04552743 2022-09-10
MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma
Stanford University
Phase 2 Completed
NCT00669669 2022-05-18
O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT02703779 2021-06-18
Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)
University of Kansas Medical Center
Phase 2 Completed
NCT02750254 2020-10-20
Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
Washington University School of Medicine
Phase 1 Terminated
NCT00822770 2020-10-14
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04058145 2020-09-07
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
Massachusetts General Hospital
Phase 2 Withdrawn
NCT03506802 2020-07-24
NYSCT MM
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT00903968 2020-06-02
Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT02416908 2020-03-13
Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
Washington University School of Medicine
Phase 1/2 Completed
NCT03277209 2020-03-02
To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas
Weill Medical College of Cornell University
Phase 1 Terminated
NCT02605460 2020-01-14
Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Phase 2 Unknown
NCT01146834 2019-12-27
Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma
Weill Medical College of Cornell University
Phase 3 Completed
NCT02682953 2019-12-11
Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers
University of Maryland, Baltimore
Phase 2 Withdrawn
NCT01160354 2019-08-28
Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT02179970 2019-07-23
CAM-PLEX
Cambridge University Hospitals NHS Foundation Trust
Phase 1 Completed
NCT01408043 2019-06-14
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
Case Comprehensive Cancer Center
Phase NA Terminated
NCT02343666 2018-11-20
HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection
Fred Hutchinson Cancer Center
Phase 1 Withdrawn
NCT01977677 2018-10-23
Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
Stanford University
Phase 1/2 Completed
NCT01319864 2018-09-07
POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients
Seattle Children's Hospital
Phase 1 Completed
NCT01352650 2018-07-02
Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)
Weill Medical College of Cornell University
Phase 1 Completed
NCT01373229 2018-02-05
Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)
Duke University
Phase 1 Completed
NCT01097057 2018-01-23
Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT01339039 2017-11-17
Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT03244930 2017-08-10
Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation
Hospital Universitario Dr. Jose E. Gonzalez
Phase 2 Unknown
NCT01403896 2017-08-02
Healthy Donor Study II - Comparing Plerixafor With G-CSF and Plerixafor
Nova Scotia Health Authority
Phase 2 Completed
NCT01339572 2017-08-01
Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation
University of Florida
Phase 2 Completed
NCT02098109 2017-07-18
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Washington University School of Medicine
Phase 2 Completed
NCT01076270 2017-06-28
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Fred Hutchinson Cancer Center
Phase NA Terminated
NCT00241358 2017-06-06
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
Washington University School of Medicine
Phase 1/2 Completed
NCT01158118 2017-06-05
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors
Washington University School of Medicine
Phase 2 Completed
NCT00914849 2017-05-17
Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies
Washington University School of Medicine
Phase 2 Completed
NCT01610999 2017-05-09
Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation
Tufts Medical Center
Phase 1 Terminated
NCT01435343 2017-04-25
Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia
PETHEMA Foundation
Phase 1/2 Completed
NCT00906945 2017-04-04
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia
Washington University School of Medicine
Phase 1/2 Completed